| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Real-Time Polymerase Chain Reaction | 9 | 2026 | 211 | 1.980 |
Why?
|
| Molecular Diagnostic Techniques | 8 | 2026 | 34 | 1.420 |
Why?
|
| Influenza A virus | 4 | 2026 | 119 | 1.360 |
Why?
|
| Influenza B virus | 3 | 2026 | 10 | 1.260 |
Why?
|
| Coronavirus | 5 | 2020 | 14 | 1.150 |
Why?
|
| Influenza, Human | 4 | 2026 | 203 | 1.150 |
Why?
|
| Severe Acute Respiratory Syndrome | 4 | 2020 | 23 | 1.130 |
Why?
|
| Sensitivity and Specificity | 17 | 2026 | 1163 | 1.080 |
Why?
|
| Multiplex Polymerase Chain Reaction | 5 | 2024 | 14 | 1.080 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2026 | 26 | 1.060 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 205 | 0.980 |
Why?
|
| RNA, Viral | 17 | 2026 | 266 | 0.940 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2026 | 39 | 0.940 |
Why?
|
| Pandemics | 11 | 2022 | 674 | 0.910 |
Why?
|
| Pneumonia, Viral | 8 | 2020 | 219 | 0.830 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 45 | 0.810 |
Why?
|
| High-Throughput Screening Assays | 7 | 2026 | 79 | 0.750 |
Why?
|
| Antiviral Agents | 4 | 2025 | 321 | 0.730 |
Why?
|
| Genome, Viral | 3 | 2025 | 144 | 0.730 |
Why?
|
| Germany | 11 | 2025 | 54 | 0.690 |
Why?
|
| Betacoronavirus | 8 | 2020 | 180 | 0.690 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2022 | 542 | 0.660 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 51 | 0.660 |
Why?
|
| Meningitis | 1 | 2020 | 18 | 0.620 |
Why?
|
| Encephalitis | 1 | 2020 | 37 | 0.610 |
Why?
|
| Staining and Labeling | 1 | 2020 | 127 | 0.590 |
Why?
|
| Humans | 74 | 2026 | 65140 | 0.580 |
Why?
|
| Automation, Laboratory | 4 | 2026 | 9 | 0.570 |
Why?
|
| Monkeypox virus | 4 | 2024 | 8 | 0.490 |
Why?
|
| Virus Replication | 8 | 2025 | 323 | 0.470 |
Why?
|
| Chiroptera | 3 | 2010 | 17 | 0.440 |
Why?
|
| Viral Envelope Proteins | 7 | 2022 | 101 | 0.440 |
Why?
|
| Virus Internalization | 5 | 2022 | 91 | 0.420 |
Why?
|
| Viral Proteins | 3 | 2022 | 270 | 0.380 |
Why?
|
| Autopsy | 6 | 2022 | 56 | 0.370 |
Why?
|
| Membrane Glycoproteins | 7 | 2022 | 662 | 0.370 |
Why?
|
| Cyclophilins | 1 | 2011 | 12 | 0.350 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 325 | 0.350 |
Why?
|
| Viral Load | 6 | 2023 | 230 | 0.350 |
Why?
|
| Blood-Brain Barrier | 2 | 2022 | 87 | 0.340 |
Why?
|
| Immunosuppressive Agents | 2 | 2025 | 380 | 0.340 |
Why?
|
| Feces | 4 | 2026 | 118 | 0.330 |
Why?
|
| Limit of Detection | 3 | 2026 | 49 | 0.330 |
Why?
|
| Viruses | 3 | 2025 | 81 | 0.320 |
Why?
|
| Sequence Deletion | 2 | 2009 | 115 | 0.310 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2025 | 94 | 0.310 |
Why?
|
| Viral Tropism | 2 | 2020 | 55 | 0.310 |
Why?
|
| Coronavirus 229E, Human | 1 | 2009 | 2 | 0.310 |
Why?
|
| Respiratory Tract Infections | 3 | 2024 | 85 | 0.290 |
Why?
|
| Reproducibility of Results | 6 | 2026 | 1698 | 0.290 |
Why?
|
| Virulence Factors | 1 | 2009 | 86 | 0.290 |
Why?
|
| Nasopharynx | 4 | 2021 | 21 | 0.290 |
Why?
|
| Vero Cells | 6 | 2025 | 81 | 0.270 |
Why?
|
| Pediatrics | 2 | 2007 | 264 | 0.260 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 229 | 0.260 |
Why?
|
| Homes for the Aged | 2 | 2008 | 166 | 0.260 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 279 | 0.250 |
Why?
|
| HIV Infections | 2 | 2025 | 955 | 0.250 |
Why?
|
| Poverty | 1 | 2009 | 304 | 0.250 |
Why?
|
| Patient Care Management | 1 | 2006 | 30 | 0.250 |
Why?
|
| Attitude of Health Personnel | 2 | 2008 | 624 | 0.240 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2026 | 25 | 0.240 |
Why?
|
| Hepatitis E | 1 | 2026 | 2 | 0.240 |
Why?
|
| Hepatitis E virus | 1 | 2026 | 2 | 0.240 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 103 | 0.240 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2012 | 45 | 0.230 |
Why?
|
| Mothers | 1 | 2009 | 280 | 0.230 |
Why?
|
| Spike Glycoprotein, Coronavirus | 9 | 2022 | 114 | 0.230 |
Why?
|
| Phylogeny | 3 | 2020 | 388 | 0.230 |
Why?
|
| Female | 20 | 2025 | 34018 | 0.230 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2025 | 12 | 0.230 |
Why?
|
| Boron Compounds | 1 | 2025 | 22 | 0.230 |
Why?
|
| Glycine | 1 | 2025 | 48 | 0.230 |
Why?
|
| Lung | 4 | 2022 | 966 | 0.230 |
Why?
|
| Gastroenteritis | 1 | 2025 | 15 | 0.230 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2026 | 86 | 0.230 |
Why?
|
| Nursing Homes | 2 | 2008 | 686 | 0.230 |
Why?
|
| Male | 19 | 2025 | 31047 | 0.220 |
Why?
|
| Mycophenolic Acid | 1 | 2025 | 68 | 0.220 |
Why?
|
| Travel | 2 | 2020 | 44 | 0.220 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 133 | 0.220 |
Why?
|
| Diarrhea | 1 | 2025 | 73 | 0.220 |
Why?
|
| Rubella | 1 | 2024 | 1 | 0.210 |
Why?
|
| Mumps | 1 | 2024 | 2 | 0.210 |
Why?
|
| Chickenpox | 1 | 2024 | 4 | 0.210 |
Why?
|
| Measles | 1 | 2024 | 3 | 0.210 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2024 | 3 | 0.210 |
Why?
|
| Brain | 3 | 2021 | 1605 | 0.210 |
Why?
|
| Serologic Tests | 2 | 2021 | 34 | 0.200 |
Why?
|
| Primary Dysautonomias | 1 | 2023 | 6 | 0.200 |
Why?
|
| Laboratories | 2 | 2021 | 27 | 0.200 |
Why?
|
| Herpesviridae | 1 | 2023 | 15 | 0.190 |
Why?
|
| Mental Health Services | 1 | 2007 | 304 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 217 | 0.190 |
Why?
|
| Middle Aged | 15 | 2025 | 18273 | 0.190 |
Why?
|
| Adult | 12 | 2025 | 17358 | 0.190 |
Why?
|
| Animals | 15 | 2026 | 21345 | 0.180 |
Why?
|
| Depression | 1 | 2009 | 900 | 0.180 |
Why?
|
| Viral Vaccines | 1 | 2022 | 56 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 105 | 0.180 |
Why?
|
| Gonorrhea | 1 | 2024 | 162 | 0.180 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 199 | 0.180 |
Why?
|
| Microvessels | 1 | 2021 | 18 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 50 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2024 | 3308 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 591 | 0.170 |
Why?
|
| Physicians | 1 | 2007 | 474 | 0.170 |
Why?
|
| Viremia | 1 | 2021 | 46 | 0.170 |
Why?
|
| Cytarabine | 1 | 2020 | 36 | 0.170 |
Why?
|
| Cornea | 1 | 2021 | 35 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 72 | 0.170 |
Why?
|
| BK Virus | 1 | 2021 | 23 | 0.170 |
Why?
|
| Polyomavirus Infections | 1 | 2021 | 31 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2020 | 17 | 0.160 |
Why?
|
| Th17 Cells | 1 | 2021 | 63 | 0.160 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 51 | 0.160 |
Why?
|
| Italy | 1 | 2020 | 69 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2006 | 721 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 42 | 0.160 |
Why?
|
| Antigens, Viral | 1 | 2021 | 130 | 0.160 |
Why?
|
| Gentian Violet | 1 | 2020 | 3 | 0.160 |
Why?
|
| Phenazines | 1 | 2020 | 6 | 0.160 |
Why?
|
| Multigene Family | 1 | 2020 | 106 | 0.160 |
Why?
|
| Cell Line | 7 | 2020 | 2024 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2020 | 55 | 0.160 |
Why?
|
| Central Nervous System | 1 | 2022 | 200 | 0.150 |
Why?
|
| Aged | 12 | 2024 | 14965 | 0.150 |
Why?
|
| Bacterial Toxins | 1 | 2020 | 58 | 0.150 |
Why?
|
| Colistin | 1 | 2019 | 6 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 345 | 0.150 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2019 | 11 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 111 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5614 | 0.150 |
Why?
|
| Clostridium Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Enterobacteriaceae | 1 | 2019 | 19 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 2 | 2011 | 279 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2006 | 822 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2021 | 284 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 788 | 0.140 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 73 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 312 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 142 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 97 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 150 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 191 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 132 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2009 | 414 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 509 | 0.130 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 350 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 353 | 0.130 |
Why?
|
| Kidney | 1 | 2020 | 451 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 196 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 2701 | 0.130 |
Why?
|
| Health Personnel | 1 | 2021 | 384 | 0.130 |
Why?
|
| Young Adult | 6 | 2025 | 4809 | 0.120 |
Why?
|
| Mesocricetus | 2 | 2021 | 92 | 0.120 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 1979 | 0.120 |
Why?
|
| Cricetinae | 2 | 2021 | 362 | 0.110 |
Why?
|
| Virus Diseases | 2 | 2024 | 117 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2020 | 742 | 0.100 |
Why?
|
| Caco-2 Cells | 2 | 2011 | 67 | 0.100 |
Why?
|
| DNA Primers | 2 | 2026 | 301 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2023 | 231 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2012 | 73 | 0.090 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2011 | 71 | 0.090 |
Why?
|
| Jurkat Cells | 1 | 2011 | 109 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2011 | 77 | 0.090 |
Why?
|
| Protein Interaction Mapping | 1 | 2011 | 69 | 0.090 |
Why?
|
| Prevalence | 3 | 2025 | 1445 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2023 | 208 | 0.080 |
Why?
|
| Oropharynx | 2 | 2021 | 12 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 106 | 0.080 |
Why?
|
| Professional-Patient Relations | 2 | 2008 | 127 | 0.080 |
Why?
|
| Job Satisfaction | 2 | 2008 | 141 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2024 | 896 | 0.080 |
Why?
|
| Mannose-Binding Lectin | 1 | 2010 | 10 | 0.080 |
Why?
|
| Virology | 1 | 2010 | 13 | 0.080 |
Why?
|
| Vaccination | 2 | 2024 | 377 | 0.080 |
Why?
|
| Workflow | 2 | 2021 | 75 | 0.080 |
Why?
|
| Asparagine | 1 | 2010 | 25 | 0.080 |
Why?
|
| Rabies virus | 1 | 2010 | 9 | 0.080 |
Why?
|
| Rabies | 1 | 2010 | 8 | 0.080 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 121 | 0.080 |
Why?
|
| Ghana | 1 | 2009 | 14 | 0.080 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2009 | 19 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 616 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 465 | 0.070 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 50 | 0.070 |
Why?
|
| Virulence | 1 | 2009 | 199 | 0.070 |
Why?
|
| Job Description | 1 | 2008 | 24 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2009 | 324 | 0.070 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 51 | 0.070 |
Why?
|
| Hospitals | 2 | 2022 | 387 | 0.070 |
Why?
|
| Adolescent | 4 | 2024 | 6297 | 0.070 |
Why?
|
| Peptides | 1 | 2012 | 591 | 0.070 |
Why?
|
| Workload | 1 | 2008 | 131 | 0.070 |
Why?
|
| New Hampshire | 1 | 2007 | 43 | 0.060 |
Why?
|
| Cholesterol | 1 | 2008 | 261 | 0.060 |
Why?
|
| Patient Participation | 1 | 2009 | 234 | 0.060 |
Why?
|
| Practice Management, Medical | 1 | 2006 | 20 | 0.060 |
Why?
|
| Focus Groups | 1 | 2008 | 319 | 0.060 |
Why?
|
| Liver | 2 | 2022 | 871 | 0.060 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2026 | 11 | 0.060 |
Why?
|
| Child | 3 | 2020 | 4607 | 0.060 |
Why?
|
| Plasma | 1 | 2026 | 38 | 0.060 |
Why?
|
| Health Services Research | 1 | 2006 | 265 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2007 | 150 | 0.060 |
Why?
|
| Inflammation | 2 | 2023 | 1192 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2022 | 2620 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 51 | 0.050 |
Why?
|
| Serotyping | 1 | 2024 | 52 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2025 | 144 | 0.050 |
Why?
|
| Abscess | 1 | 2024 | 78 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 992 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2024 | 60 | 0.050 |
Why?
|
| Bacteria | 1 | 2007 | 336 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2023 | 20 | 0.050 |
Why?
|
| Virus Inactivation | 1 | 2023 | 2 | 0.050 |
Why?
|
| Patients' Rooms | 1 | 2022 | 8 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2009 | 918 | 0.050 |
Why?
|
| Disinfection | 1 | 2022 | 23 | 0.050 |
Why?
|
| Medicaid | 1 | 2006 | 372 | 0.050 |
Why?
|
| Age Factors | 1 | 2006 | 1586 | 0.050 |
Why?
|
| Mouthwashes | 1 | 2022 | 5 | 0.050 |
Why?
|
| Imines | 1 | 2022 | 4 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2006 | 528 | 0.050 |
Why?
|
| Ethylene Glycols | 1 | 2022 | 11 | 0.050 |
Why?
|
| Tropism | 1 | 2022 | 15 | 0.050 |
Why?
|
| Benzamidines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 147 | 0.050 |
Why?
|
| Rats | 1 | 2026 | 1994 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 125 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2024 | 422 | 0.050 |
Why?
|
| Guanidines | 1 | 2022 | 13 | 0.040 |
Why?
|
| Trust | 1 | 2022 | 79 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 166 | 0.040 |
Why?
|
| Lactation | 1 | 2022 | 78 | 0.040 |
Why?
|
| Saliva | 1 | 2022 | 100 | 0.040 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2024 | 204 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 102 | 0.040 |
Why?
|
| Corneal Transplantation | 1 | 2021 | 2 | 0.040 |
Why?
|
| Virus Shedding | 1 | 2021 | 17 | 0.040 |
Why?
|
| Pyridines | 1 | 2022 | 119 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 706 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2021 | 25 | 0.040 |
Why?
|
| Antibodies | 1 | 2022 | 187 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2021 | 21 | 0.040 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 6 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 91 | 0.040 |
Why?
|
| Clone Cells | 1 | 2021 | 111 | 0.040 |
Why?
|
| Azacitidine | 1 | 2020 | 15 | 0.040 |
Why?
|
| Milk, Human | 1 | 2022 | 99 | 0.040 |
Why?
|
| Neuropathology | 1 | 2020 | 3 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 40 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 85 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 61 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 5792 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2020 | 37 | 0.040 |
Why?
|
| Cadaver | 1 | 2020 | 134 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2020 | 77 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2021 | 98 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 107 | 0.040 |
Why?
|
| Retina | 1 | 2021 | 132 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 160 | 0.040 |
Why?
|
| Pharynx | 1 | 2020 | 25 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 90 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 25 | 0.040 |
Why?
|
| Infant | 2 | 2020 | 1693 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 250 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 293 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2022 | 166 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 66 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 405 | 0.040 |
Why?
|
| Glycosylation | 2 | 2010 | 138 | 0.040 |
Why?
|
| Influenza in Birds | 1 | 2019 | 3 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2020 | 2061 | 0.040 |
Why?
|
| Birds | 1 | 2019 | 10 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2021 | 302 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 450 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 221 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2757 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 513 | 0.040 |
Why?
|
| Macrophages | 1 | 2024 | 1038 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 858 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 206 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1290 | 0.030 |
Why?
|
| Heart | 1 | 2020 | 297 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 384 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 875 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2022 | 1422 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1141 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 330 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 431 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 399 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 402 | 0.030 |
Why?
|
| Mutation | 1 | 2025 | 2661 | 0.030 |
Why?
|
| Models, Biological | 1 | 2022 | 1192 | 0.030 |
Why?
|
| Protein Binding | 2 | 2012 | 1640 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2157 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1784 | 0.030 |
Why?
|
| Risk Factors | 1 | 2025 | 5429 | 0.030 |
Why?
|
| Archaeal Proteins | 1 | 2014 | 6 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 698 | 0.030 |
Why?
|
| Exoribonucleases | 1 | 2014 | 30 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 35 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3485 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2014 | 67 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2014 | 133 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2014 | 419 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1392 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 3762 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1656 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2012 | 32 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 39 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2010 | 18 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 199 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 79 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 156 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 95 | 0.020 |
Why?
|
| China | 1 | 2010 | 176 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 611 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6872 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2009 | 65 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 251 | 0.020 |
Why?
|
| beta-Cyclodextrins | 1 | 2008 | 21 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 238 | 0.020 |
Why?
|
| Consumer Behavior | 1 | 2008 | 38 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 431 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 1332 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 700 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 11119 | 0.020 |
Why?
|
| Aircraft | 1 | 2007 | 18 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 262 | 0.020 |
Why?
|
| Quality of Life | 1 | 2008 | 1260 | 0.010 |
Why?
|